UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-42506 CALLAN JMB INC. (Exact name of registrant as specified in its charter) 244 Flightline Drive Spring Branch ...

Financial Performance - Revenues for Q3 2025 were $1.4 million, a slight increase from $1.4 million in Q3 2024, while revenues for the nine months ended September 30, 2025, were $4.6 million, down from $5.2 million in the same period last year [12]. - Gross profit for Q3 2025 was $0.5 million, compared to $0.5 million in Q3 2024, and for the nine months ended September 30, 2025, gross profit was $1.8 million, down from $2.1 million in the prior year [12]. - Loss from operations for Q3 2025 was ($1.9) million, compared to a loss of ($0.8) million in Q3 2024, and for the nine months ended September 30, 2025, the loss was ($4.5) million, up from ($1.0) million in the prior year [12]. - Net income for the nine months ended September 30, 2025, was a loss of $5,373,327, compared to a loss of $998,596 for the same period in 2024 [14]. - Net cash provided by (used in) operating activities was $(3,887,737) for the nine months ended September 30, 2025, compared to $1,263,526 in 2024 [14]. - Cash flows used in investing activities totaled $(616,896) for the nine months ended September 30, 2025, compared to $(46,167) in 2024 [14]. - Net cash provided by financing activities was $5,196,432 for the nine months ended September 30, 2025, compared to $(3,563,676) in 2024 [14]. - The company reported stock-based compensation of $1,154,842 for the nine months ended September 30, 2025 [14]. - The company experienced a decrease in accounts receivable of $(395,995) compared to an increase of $1,803,724 in 2024 [14]. - The company reported a decrease in inventory of $(64,883) for the nine months ended September 30, 2025, compared to an increase of $7,086 in 2024 [14]. - Proceeds from IPO and overallotment, net, amounted to $4,543,988 for the nine months ended September 30, 2025 [14]. - The company had a cash flow increase of $691,799 in cash and cash equivalents for the nine months ended September 30, 2025, compared to a decrease of $(2,346,317) in 2024 [14]. Operational Developments - The Company extended its emergency preparedness contract with the City of Chicago through June 2026, increasing total contract value to $9.1 million with an additional $1.5 million in funding [6]. - The Company established a subsidiary in India, Callan JMB Services (India) Private Limited, with plans for a temperature-controlled warehouse for pharmaceutical storage and distribution [6]. - The Company upgraded its Sentry Monitoring System to version 4.0, enhancing temperature monitoring capabilities for healthcare facilities and emergency management agencies [6]. - The Company entered a preliminary agreement to install oral drug delivery equipment at its cGMP facility in Texas, supporting future logistics operations for international pharmaceutical companies [6]. Cash and Assets - Cash and cash equivalents as of September 30, 2025, were $2.8 million, an increase from $2.1 million at the end of 2024 [10]. - Total assets as of September 30, 2025, were $7.7 million, compared to $5.1 million at the end of 2024 [10]. - Cash and cash equivalents at the end of the period were $2,789,744, a decrease from $2,809,303 at the end of the same period in 2024 [14].

Expanded the Company’s compliance-driven logistics platform into the food sampling industryEntered agreement to install oral drug delivery equipment at Texas facility Established a subsidiary in India and advanced plans for a temperature-controlled pharmaceutical storage and distribution warehouseExtended the Company’s long-term contract with the City of Chicago through June 2026, including an increase in funding Upgraded Sentry Monitoring System Technology with Sentry 4 for Mobile Temperature Monitoring SP ...

Agreement is the latest step in execution of the Company’s strategy to support onshoring of logistical and operational activities for international companies to the U.S. SPRING BRANCH, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company empowering the healthcare industry and emergency management agencies through fulfillment, storage, monitoring, and cold chain logistics services, today announced that it has entered a preli ...

Move leverages the Company’s expertise in regulated materials to capture opportunities in sustainable, high-growth consumer markets Spring Branch, TX, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Callan JMB Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), an integrative logistics company serving healthcare and emergency management sectors through fulfillment, storage, monitoring, and cold chain logistics, today announced the expansion of its reclamation operations into the food sampling industry. This move is part ...

Core Viewpoint - Callan JMB Inc. is expanding its reclamation operations into the food sampling industry through a partnership with Keychain, aiming to enhance compliance and sustainability in this high-growth market [1][2][3]. Company Strategy - The partnership with Keychain, an AI-enabled platform, is part of Callan JMB's growth strategy to penetrate neighboring markets that are experiencing significant growth [2]. - The company is already collaborating with established players in the food sampling sector to improve compliance and sustainability in their distribution models [3]. Management Commentary - CEO Wayne Williams emphasized the importance of compliance infrastructure in ensuring safety and accountability, drawing parallels between the food sampling and pharmaceutical industries [3]. - The initiative aims to reduce waste and protect product quality while meeting consumer expectations, reflecting a broader strategy to apply sustainable logistics across various industries [3]. Recent Earnings - In August 2025, Callan JMB reported a second-quarter loss of $0.31 per share, compared to a loss of $0.04 in the previous year, with revenue of $1.666 million, down from $1.986 million year-over-year [4]. - Despite the earnings report, CJMB shares closed higher by 4.45% at $3.99 [4].

Core Insights - Callan JMB INC. has upgraded its Sentry Monitoring System to version 4.0, enhancing flexibility and accessibility for remote monitoring of temperature-sensitive pharmaceutical products [1][2][4] Product Features - The Sentry Monitoring System allows for 24/7/365 active monitoring, alarm notifications, and compliant reporting data, now with improved accessibility through HTML5, enabling users to manage alarms from any device with a web browser [2][3] - Users can access a consistent interface across various devices, including PCs, Macs, iPhones, Androids, and tablets, allowing for real-time monitoring and management of environmental anomalies in pharmaceutical storage [3] Company Overview - Callan JMB is an integrative logistics company focused on empowering the healthcare industry and emergency management agencies through services such as fulfillment, storage, monitoring, and cold chain logistics [5] - The company emphasizes its expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance, and emergency preparedness, aiming to provide a high standard of client experience [5]

Core Insights - Callan JMB INC. is participating in the LD Micro Main Event XIX Conference scheduled for October 19-21, 2025, where they will present on October 21 at 12:00 PM PT [1][2] Company Overview - Callan JMB is an integrative logistics company focused on empowering the healthcare industry and emergency management agencies through services such as fulfillment, storage, monitoring, and cold chain logistics [3] - The company aims to secure medical materials and protect patients and communities by providing compliant, safe, and effective medicines [3] - Callan JMB boasts unparalleled expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance, and emergency preparedness [3] - The company emphasizes a high standard of client experience with customizable interfaces, reliable shipping, and environmentally sustainable specialty packaging [3]

Core Insights - Callan JMB INC. is an integrative logistics company focused on empowering the healthcare industry and emergency management agencies through various logistics services [1][3] - The company will participate in two investment conferences in September 2025, providing opportunities for investor engagement [2] Company Overview - Callan JMB specializes in fulfillment, storage, monitoring, and cold chain logistics services aimed at securing medical materials and ensuring patient safety [3] - The company boasts expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance, and emergency preparedness [3] - Callan JMB emphasizes a high standard of client experience with customizable interfaces and reliable shipping, alongside a commitment to environmental sustainability in packaging [3] Upcoming Events - The H.C. Wainwright 27 Annual Global Investment Conference will take place from September 8-10, 2025, with a presentation available on demand starting September 5, 2025 [2] - The iAccess Alpha Virtual Best Ideas Fall Investment Conference is scheduled for September 16-17, 2025, with a presentation on September 16, 2025, at 10:30 a.m. ET [2] - Management will conduct one-on-one investor meetings during both conferences, with scheduling available through designated representatives [2]

PART I - FINANCIAL INFORMATION [Item 1. Unaudited Financial Statements](index=3&type=section&id=Item%201.%20Unaudited%20Financial%20Statements) Presents unaudited condensed consolidated financial statements, covering balance sheets, operations, equity, cash flows, and detailed notes [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Summarizes the company's financial position, including assets, liabilities, and equity, as of June 30, 2025, and December 31, 2024 Condensed Consolidated Balance Sheet Highlights (June 30, 2025 vs. December 31, 2024) | Metric | June 30, 2025 (USD) | December 31, 2024 (USD) | Change (USD) | Change % | | :-------------------------- | :-------------- | :---------------- | :----- | :------- | | Cash and cash equivalents | $4,224,151 | $2,097,945 | $2,126,206 | 101.3% | | Total assets | $8,965,681 | $5,082,549 | $3,883,132 | 76.4% | | Total liabilities | $3,140,394 | $1,909,191 | $1,231,203 | 64.5% | | Total Stockholders' Equity | $5,825,287 | $3,173,358 | $2,651,929 | 83.6% | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Details the company's revenues, expenses, and net loss for the three and six months ended June 30, 2025 and 2024 Condensed Consolidated Statements of Operations Highlights (Three Months Ended June 30) | Metric | June 30, 2025 (USD) | June 30, 2024 (USD) | Change (USD) | Change % | | :---------------------- | :------------ | :------------ | :---------- | :------- | | Revenue | $1,666,309 | $1,985,768 | $(319,459) | -16% | | Gross profit | $643,870 | $962,216 | $(318,346) | -33% | | Loss from operations | $(1,402,667) | $(133,423) | $(1,269,244) | 951% | | Net loss | $(1,397,523) | $(112,476) | $(1,285,047) | 1143% | | Net loss per common share | $(0.31) | $(0.04) | $(0.27) | 675% | Condensed Consolidated Statements of Operations Highlights (Six Months Ended June 30) | Metric | June 30, 2025 (USD) | June 30, 2024 (USD) | Change (USD) | Change % | | :---------------------- | :------------ | :------------ | :---------- | :------- | | Revenue | $3,115,687 | $3,776,289 | $(660,602) | -17% | | Gross profit | $1,256,963 | $1,679,799 | $(422,836) | -25% | | Loss from operations | $(2,644,915) | $(220,882) | $(2,424,033) | 1097% | | Net loss | $(2,641,986) | $(193,609) | $(2,448,377) | 1264% | | Net loss per common share | $(0.63) | $(0.08) | $(0.55) | 687.5% | [Condensed Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity) Outlines changes in stockholders' equity, including net loss, IPO proceeds, and stock-based compensation, from January 1, 2025, to June 30, 2025 Stockholders' Equity Changes (January 1, 2025 to June 30, 2025) | Item | Amount (USD) | | :--------------------------------------- | :----------- | | Stockholders' Equity at January 1, 2025 | $3,173,358 | | Net loss | $(2,638,113) | | Common stock issued in IPO (net of costs)| $3,951,868 | | Common stock issued in IPO (over allotment, net of costs) | $592,120 | | Stock based compensation | $749,927 | | Stockholders' Equity at June 30, 2025 | $5,825,287 | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Presents a summary of cash flows from operating, investing, and financing activities for the six months ended June 30, 2025 and 2024 Cash Flow Summary (Six Months Ended June 30) | Activity | June 30, 2025 (USD) | June 30, 2024 (USD) | Change (USD) | | :----------------------------- | :------------ | :------------ | :----------- | | Net cash from operating activities | $(2,124,970) | $275,524 | $(2,400,494) | | Net cash used in investing activities | $(447,506) | $(45,874) | $(401,632) | | Net cash from financing activities | $4,698,682 | $(3,537,549) | $8,236,231 | | Cash and cash equivalents at end of period | $4,224,151 | $1,847,721 | $2,376,430 | [Notes to Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Provides detailed explanatory notes supporting the condensed consolidated financial statements [NOTE 1 – NATURE OF OPERATIONS](index=8&type=section&id=NOTE%201%20%E2%80%93%20NATURE%20OF%20OPERATIONS) Describes the company's formation, primary operating subsidiary, and its core business in logistics and fulfillment for time-sensitive industries - Callan JMB Inc. was formed on January 24, 2024, in Nevada, to become a holding company for Coldchain Technology Services, LLC (CTS) and Callan JMB Services (India) Private Limited[21](index=21&type=chunk) - CTS, the main operating subsidiary, is engaged in a vertically integrated logistics and fulfillment ecosystem for the supply chain, utilizing advanced predictive technology to ensure product integrity in time-sensitive industries[21](index=21&type=chunk) [NOTE 2 – RECLASSIFICATIONS AND REVISIONS](index=8&type=section&id=NOTE%202%20%E2%80%93%20RECLASSIFICATIONS%20AND%20REVISIONS%20TO%20MARCH%2031%2C%202025%20CONDENSED%20CONSOLIDATED%20FINANCIAL%20STATEMENTS) Details immaterial revisions made to previously issued financial statements for the three months ended March 31, 2025 - The Company identified immaterial revisions to its previously issued financial statements for the three months ended March 31, 2025, primarily related to lease modifications and the timing of expense recognition for invoices and prepaid assets[24](index=24&type=chunk) Revisions to March 31, 2025 Consolidated Financial Statements | Financial Statement Line Item | As Previously Reported (USD) | Revisions (USD) | As Revised (USD) | | :-------------------------------- | :--------------------- | :----------- | :----------- | | Right of use asset | $799,739 | $324,352 | $1,124,091 | | Other current assets | $180,328 | $104,106 | $284,434 | | Total Assets | $8,455,666 | $428,458 | $8,884,124 | | Operating lease liabilities – current | $236,343 | $44,453 | $280,796 | | Operating lease liabilities - non-current | $592,587 | $280,924 | $873,511 | | Accrued expenses | $390,461 | $106,954 | $497,415 | | Total Liabilities | $1,648,085 | $432,331 | $2,080,416 | | Retained earnings | $(3,534,238) | $(3,873) | $(3,538,111) | | Total Equity | $6,807,581 | $(3,873) | $6,803,708 | [NOTE 3 – REORGANIZATION](index=8&type=section&id=NOTE%203%20